Walgreens Boots Alliance, Inc. (NASDAQ: WBA) on Tuesday said its third-quarter sales rose 9%. As a result, the healthcare service company’s adjusted
Walgreens Boots Alliance (WBA) Q3 adj. profit rises on higher revenues
Categories
Health Care
Superlatus names Dr. Eugenio Bortone COO; interim CEO Tim Alford to become CCO
Superlatus, Inc., a holding company of food products and distribution capabilities, on Tuesday, announced new appointments to its management team. The company
Ocean Biomedical (OCEA) joins the Russell 2000 Index
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said it has been included in the Russell 2000 Index and the broad-market Russell 3000
Ocean Biomedical granted US patent for bispecific cancer immunotherapy treatment
Biotechnology company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Monday said its scientific co-founder Dr. Jack Elias has been granted a new, broad
Superlatus to be acquired by TRxADE HEALTH to create a global food consolidation platform
Superlatus, Inc., a U.S.-based holding company of food products and distribution capabilities, has signed a letter of intent to be acquired by
Ocean Biomedical extends patent rights for idiopathic pulmonary fibrosis discovery to Europe
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Friday revealed that its scientific co-founder Dr. Jack Elias has received notice from the
Walgreens Boots Alliance (WBA) set to report Q3 results. What’s in the cards
Walgreens Boots Alliance, Inc. (NASDAQ: WBA), a leading retailer and wholesaler of health and wellness products, is scheduled to report third-quarter earnings
Avid Bioservices Inc. (CDMO) Q4 2023 Earnings Call Transcript
Avid Bioservices Inc. (NASDAQ: CDMO) Q4 2023 earnings call dated Jun. 21, 2023 Corporate Participants: Tim Brons -- Investor Relations Nicholas Green -- President and Chief
Patterson Companies, Inc. (PDCO) Q4 2023 Earnings Call Transcript
Patterson Companies, Inc. (NASDAQ: PDCO) Q4 2023 earnings call dated Jun. 21, 2023 Corporate Participants: John M. Wright -- Vice President of Investor Relations
Fundamental Research Corp. raises Ocean Biomedical’s price target to $17.63 per share
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Wednesday said that Fundamental Research Corp. increased the price target of the company’s stock to $17.63
Earnings Summary: A snapshot of Catalent’s Q3 2023 results
Catalent, Inc. (NYSE: CTLT), a provider of delivery technologies and development solutions to the pharmaceutical industry, has reported earnings for the third
Ocean Biomedical’s scientific co-founder Dr. Jonathan Kurtis gets new patent for malaria vaccine
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company focused on clinical programs in oncology, fibrosis, and infectious disease, Thursday said its scientific
Earnings Summary: CooperCompanies (COO) reports Q2 2023 financial results
Medical device maker CooperCompanies (NYSE: COO) has announced financial results for the second quarter of 2023, reporting lower earnings despite an increase
Taglich Brothers initiates coverage of Ocean Biomedical, with price target of $20
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Thursday revealed that Taglich Brothers initiated coverage on the company with a share price
Ocean Biomedical, Inc. (NASDAQ: OCEA) Research Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biopharmaceutical company focused on clinical programs in oncology, fibrosis, infectious disease, and inflammation. Its business
Infographic: How Medtronic (MDT) performed in Q4 2023
Medtronic plc (NYSE: MDT) reported fourth quarter 2023 earnings results today. Revenue was $8.5 billion, up 5.6% year-over-year, both on a reported
Ocean Biomedical (OCEA) set to join the Russell 2000 Index
Biopharmaceutical company Ocean Biomedical (NASDAQ: OCEA) on Thursday said it is expected to be added to the Russell 2000 Index, effective after
Strides Pharma Science Limited (STAR) Q4 2023 Earnings Con Call Transcript
Strides Pharma Science Limited ( ?????? : STAR) Q4 2023 Earnings Con Call dated May. 25, 2023 Corporate participants: Arun Kumar --
Agilent Technologies (A) Q2 2023 earnings, revenue increase
Agilent Technologies (NYSE: A) has announced second-quarter 2023 financial results, reporting an increase in adjusted profit and revenues. The Santa Clara, California-based
Ocean Biomedical (OCEA) announces patent award for novel cancer immunotherapy treatment
Biopharma company Ocean Biomedical (NASDAQ: OCEA) on Tuesday said its scientific co-founder Dr. Jack Elias has been issued a broad patent for
Ocean Biomedical announces private placement of $25 mln convertible notes
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said it has entered into a private placement pursuant to a securities purchase